MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC ADVIA CENTAUR XP BR (27.29); SYSTEM, TEST, IMMUNOLOGICAL, ANTIGEN, TUMOR

Model Number N/A

Device Problem Incorrect, Inadequate or Imprecise Result or Readings (1535)

Patient Problem No Clinical Signs, Symptoms or Conditions (4582)

Event Date 04/04/2022

Event Type  malfunction  

Manufacturer Narrative

A united states (us) customer called the siemens customer care center (ccc) to report that discordant cancer antigen 27.29 (br) results were obtained on 11 patient samples on an advia centaur xp instrument.The customer stated that quality control (qc) results were in range on the day the samples were run but were low out of range on (b)(6) 2022.Even after the assay was recalibrated.A siemens customer service engineer (cse) was dispatched.The cse resolved the issue through a regular service call.The cse ran a calibration, quality controls (qc), and precision, which all were acceptable.The customer will monitor to see if issue persists.As of (b)(6) 2022.Qc was near the mean and cvs were acceptable.Siemens is investigating.The instructions for use (ifu) under the interpretation of results states the following: results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings.

Event Description

Discordant cancer antigen 27.29 (br) results were obtained on 11 patient samples on an advia centaur xp instrument and were considered discordant compared to repeat testing on an alternate advia centaur xp instrument.The initial results were reported to the physician(s), who did not question the results.The repeat results were reported, as the correct results, to the physician(s).There are no known reports of patient intervention or adverse health consequences due to the discordant, cancer antigen 27.29 (br) results.

Manufacturer Narrative

The initial mdr 1219913-2022-00129 was filed on april 29, 2022.Additional information: may 13, 2022.A united states (us) customer called the siemens customer care center (ccc) to report that discordant cancer antigen 27.29 (br) results were obtained on 11 patient samples on an advia centaur xp instrument.The customer stated that quality control (qc) results were in range on the day the samples were run but were low out of range on (b)(6) 2022 even after the assay was recalibrated.No other assays had issues on advia centaur xp s/n: (b)(6) when tested on (b)(6) 2022.The customer has not had similar issues since that time.The calibration, qc, and patients samples tested on (b)(6) 2022 on advia centaur xp s/n: (b)(6) were tested with the same primary readypack and the same ancillary readypack.The relative light units (rlus) from the on (b)(6) 2022 calibration were lower than the subsequent calibration with kit lot: 262 and calibrator lot: cg53.Because the qc was in range after the on (b)(6) 2022 calibration that would indicate the lower rlus were caused by the reagents, not the calibrators.Any patient samples tested with those reagents would have accurate values but when moving to new reagent packs, qc and patient samples would recover low.The customer does not know how long the primary readypack used on (b)(6) 2022 was on the advia centaur xp instrument.For the advia centaur xp br (ca 27.29) assay, if a primary readypack is on the instrument for more than 7 days it should be calibrated every 3 days and the assay should be recalibrated when a fresh primary reagent pack is loaded on the system.Siemens does not know why the rlus were lower with the primary readypack and ancillary readypack used on (b)(6) 2022.The cause of the low results seen by the customer when using advia centaur xp br (ca 27.29) kit lot: 262 could not be determined but siemens cannot rule out reagent shipping/handling.Based on the investigation, no product problem was identified.The customer's issue was resolved.No further action is needed.In section h6, investigation findings, and investigation conclusion codes were updated based on the investigation results.

• Brand Name: ADVIA CENTAUR XP BR (27.29)
• Type of Device: SYSTEM, TEST, IMMUNOLOGICAL, ANTIGEN, TUMOR
• Manufacturer (Section D): SIEMENS HEALTHCARE DIAGNOSTICS, INC; 333 coney street; east walpole MA 02032
• Manufacturer (Section G): SIEMENS HEALTHCARE DIAGNOSTICS, INC; 333 coney street; east walpole MA 02032
• Manufacturer Contact: louise mclaughlin ; 333 coney street; east walpole, MA 02032 ; 7818564812
• MDR Report Key: 14254863
• MDR Text Key: 299455141
• Report Number: 1219913-2022-00129
• Device Sequence Number: 1
• Product Code: MOI
• UDI-Device Identifier: 00630414204772
• UDI-Public: 00630414204772
• Combination Product (y/n): N
• Reporter Country Code: US
• PMA/PMN Number: K982680
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Health Professional,User Facility
• Reporter Occupation: Other Health Care Professional
• Type of Report: Initial,Followup
• Report Date: 05/20/2022

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Expiration Date: 01/01/2023
• Device Model Number: N/A
• Device Catalogue Number: 10340081
• Device Lot Number: 262
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Initial Date Manufacturer Received: 04/06/2022
• Initial Date FDA Received: 04/29/2022
• Supplement Dates Manufacturer Received: 05/13/2022
• Supplement Dates FDA Received: 05/21/2022
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Date Device Manufactured: 12/01/2021
• Is the Device Single Use?: No
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1